World Health Organization-defined eosinophilic disorders: 2019 update on diagnosis, risk stratification, and management.
Abstract | DISEASE OVERVIEW: The eosinophilias encompass a broad range of non-hematologic (secondary or reactive) and hematologic (primary, clonal) disorders with potential for end-organ damage. DIAGNOSIS:
Hypereosinophilia has generally been defined as a peripheral blood eosinophil count greater than 1.5 × 109 /L, and may be associated with tissue damage. After exclusion of secondary causes of eosinophilia, diagnostic evaluation of primary eosinophilias relies on a combination of various tests. They include morphologic review of the blood and marrow, standard cytogenetics, fluorescence in situ-hybridization, flow immunophenotyping, and T-cell clonality assessment to detect histopathologic or clonal evidence for an acute or chronic hematolymphoid neoplasm. RISK STRATIFICATION: RISK-ADAPTED THERAPY:
|
Authors | William Shomali, Jason Gotlib |
Journal | American journal of hematology
(Am J Hematol)
Vol. 94
Issue 10
Pg. 1149-1167
(10 2019)
ISSN: 1096-8652 [Electronic] United States |
PMID | 31423623
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
|
Copyright | © 2019 Wiley Periodicals, Inc. |
Chemical References |
- Adrenal Cortex Hormones
- Antineoplastic Agents
- Oncogene Proteins, Fusion
- mRNA Cleavage and Polyadenylation Factors
- FGFR1 protein, human
- FIP1L1-PDGFRA fusion protein, human
- FLT3 protein, human
- Receptor, Fibroblast Growth Factor, Type 1
- Receptor, Platelet-Derived Growth Factor alpha
- fms-Like Tyrosine Kinase 3
- JAK2 protein, human
- Janus Kinase 2
|
Topics |
- Adrenal Cortex Hormones
(therapeutic use)
- Adult
- Aged
- Antineoplastic Agents
(therapeutic use)
- Bone Marrow Examination
- Clone Cells
(pathology)
- Disease Management
- Eosinophilia
(diagnosis, epidemiology, etiology, therapy)
- Female
- Hematologic Neoplasms
(blood, diagnosis, drug therapy)
- Humans
- Immunophenotyping
- In Situ Hybridization, Fluorescence
- Janus Kinase 2
(genetics)
- Male
- Middle Aged
- Myelodysplastic Syndromes
(blood, diagnosis, drug therapy)
- Myeloproliferative Disorders
(blood, diagnosis, drug therapy)
- Oncogene Proteins, Fusion
(antagonists & inhibitors, genetics)
- Prognosis
- Receptor, Fibroblast Growth Factor, Type 1
(genetics)
- Receptor, Platelet-Derived Growth Factor alpha
(antagonists & inhibitors, genetics)
- Risk Assessment
- Symptom Assessment
- World Health Organization
- Young Adult
- fms-Like Tyrosine Kinase 3
(genetics)
- mRNA Cleavage and Polyadenylation Factors
(antagonists & inhibitors, genetics)
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|